[go: up one dir, main page]

Russomanno et al., 2021 - Google Patents

Interfering with the tumor–immune interface: making way for triazine-based small molecules as novel PD-L1 inhibitors

Russomanno et al., 2021

Document ID
4029964357664085598
Author
Russomanno P
Assoni G
Amato J
D’Amore V
Scaglia R
Brancaccio D
Pedrini M
Polcaro G
La Pietra V
Orlando P
Falzoni M
Cerofolini L
Giuntini S
Fragai M
Pagano B
Donati G
Novellino E
Quintavalle C
Condorelli G
Sabbatino F
Seneci P
Arosio D
Pepe S
Marinelli L
Publication year
Publication venue
Journal of medicinal chemistry

External Links

Snippet

The inhibition of the PD-1/PD-L1 axis by monoclonal antibodies has achieved remarkable success in treating a growing number of cancers. However, a novel class of small organic molecules, with BMS-202 (1) as the lead, is emerging as direct PD-L1 inhibitors. Herein, we …
Continue reading at pubs.acs.org (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Similar Documents

Publication Publication Date Title
Russomanno et al. Interfering with the tumor–immune interface: making way for triazine-based small molecules as novel PD-L1 inhibitors
Basu et al. Design, synthesis, evaluation, and structural studies of C 2-symmetric small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 protein–protein interaction
Wang et al. Discovery of small-molecule inhibitors of the PD-1/PD-L1 axis that promote PD-L1 internalization and degradation
Guo et al. Design, synthesis, and biological evaluation of linear aliphatic amine-linked triaryl derivatives as potent small-molecule inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction with promising antitumor effects in vivo
Guzik et al. Small-molecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1
Wang et al. Novel biphenyl pyridines as potent small-molecule inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 interaction
Qin et al. Discovery of 4-arylindolines containing a thiazole moiety as potential antitumor agents inhibiting the programmed cell death-1/programmed cell death-ligand 1 interaction
Serafini et al. Discovery of highly potent benzimidazole derivatives as indoleamine 2, 3-dioxygenase-1 (IDO1) inhibitors: from structure-based virtual screening to in vivo pharmacodynamic activity
Liu et al. Syntheses, biological evaluations, and mechanistic studies of benzo [c][1, 2, 5] oxadiazole derivatives as potent PD-L1 inhibitors with in vivo antitumor activity
Li et al. Targeted protein degradation induced by HEMTACs based on HSP90
Cheng et al. Discovery of novel and highly potent resorcinol dibenzyl ether-based PD-1/PD-L1 inhibitors with improved drug-like and pharmacokinetic properties for cancer treatment
Acúrcio et al. Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment
OuYang et al. Design, synthesis, and evaluation of o-(biphenyl-3-ylmethoxy) nitrophenyl derivatives as PD-1/PD-L1 inhibitors with potent anticancer efficacy in vivo
Cheng et al. Making protein degradation visible: discovery of theranostic PROTACs for detecting and degrading NAMPT
Bhatia et al. Development of a first-in-class small-molecule inhibitor of the C-terminal Hsp90 dimerization
Rietz et al. Fragment-based discovery of small molecules bound to T-cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3)
Ofori et al. Small-molecule poly (ADP-ribose) polymerase and PD-L1 inhibitor conjugates as dual-action anticancer agents
Abdel-Rahman et al. Discovery of small-molecule TIM-3 inhibitors for acute myeloid leukemia using pharmacophore-based virtual screening
Daniele et al. Lead optimization of 2-phenylindolylglyoxylyldipeptide murine double minute (MDM) 2/translocator protein (TSPO) dual inhibitors for the treatment of gliomas
Wang et al. Discovery of small and bifunctional molecules targeting PD-L1/CD73 for cancer dual immunotherapy
Yang et al. Discovery of novel small-molecule-based potential PD-L1/EGFR dual inhibitors with high druggability for glioblastoma immunotherapy
Liu et al. Discovery and crystallography study of novel biphenyl ether and oxadiazole thioether (non-arylmethylamine)-based small-molecule PD-1/PD-L1 inhibitors as immunotherapeutic agents
Huang et al. Construction of anti-hPD-L1 HCAb Nb6 and in situ 124I labeling for noninvasive detection of PD-L1 expression in human bone sarcoma
Ding et al. Discovery of novel d-(+)-biotin-conjugated resorcinol dibenzyl ether-based PD-L1 inhibitors for targeted cancer immunotherapy
Luo et al. Discovery of novel receptor tyrosine kinase-like orphan receptor 1 (ROR1) inhibitors for cancer treatment